ELABORATION OF A RISK SCORE FOR CELIAC DISEASE SCREENING

Objective: This study aims to elaborate a risk score that will aid in the screening of celiac disease, based on the risk factors already described in the literature. Methods: It is a case-control study with two groups: individuals who reported having celiac disease and individuals who reported not h...

Full description

Saved in:
Bibliographic Details
Main Authors: Luiza Arregui Igarsaba (Author), Mônica Maria Celestina de Oliveira (Author), Daniele Botelho Vinholes (Author)
Format: Book
Published: Universidade do Estado do Rio de Janeiro, 2019-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_19d9e2c3eb5e4ded806869bfc4b49df1
042 |a dc 
100 1 0 |a Luiza Arregui Igarsaba  |e author 
700 1 0 |a Mônica Maria Celestina de Oliveira  |e author 
700 1 0 |a Daniele Botelho Vinholes  |e author 
245 0 0 |a ELABORATION OF A RISK SCORE FOR CELIAC DISEASE SCREENING 
260 |b Universidade do Estado do Rio de Janeiro,   |c 2019-04-01T00:00:00Z. 
500 |a 2238-913X 
500 |a 10.12957/demetra.2019.32905 
520 |a Objective: This study aims to elaborate a risk score that will aid in the screening of celiac disease, based on the risk factors already described in the literature. Methods: It is a case-control study with two groups: individuals who reported having celiac disease and individuals who reported not having celiac disease. For data collection, a questionnaire was elaborated based on the bibliographic review, answered online by the research participants. The data collected were entered in the Excel program and analyzed in the SPSS 23.0 program. Results: Among these questionnaires, 72 were cases (with celiac disease) and 54 controls (without celiac disease). There was a significant difference, with p-value of 0.005, among the scores of the group of cases, 7.09 (standard deviation: 1.47), and of the control group, 4.59 (standard deviation: 1.94). Discussion: The main benefit is that, with more studies, the celiac patient can initiate treatment early, reducing the risk of complications and associated comorbidities, and reduce the rate of death of undiagnosed or late diagnosed celiac patients. Conclusion: There is a significant difference between the risk scores, showing that the cases have a higher score in relation to the controls. It is important to make it clear that this score will be used only for screening study purposes and not for celiac disease diagnosis. DOI: 10.12957/demetra.2019.32905 
546 |a EN 
546 |a ES 
546 |a PT 
690 |a doença celíaca 
690 |a fatores de risco 
690 |a programas de rastreamento 
690 |a Agriculture (General) 
690 |a S1-972 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Demetra, Vol 14, Iss 0, Pp e32905-e32905 (2019) 
787 0 |n https://www.e-publicacoes.uerj.br/index.php/demetra/article/view/32905 
787 0 |n https://doaj.org/toc/2238-913X 
856 4 1 |u https://doaj.org/article/19d9e2c3eb5e4ded806869bfc4b49df1  |z Connect to this object online.